Vir Biotechnology Inc reports results for the quarter ended in December - Earnings Summary

Vir Biotechnology

23/02/2024 03:04

* Vir Biotechnology Inc  VIR.OQ  reported a quarterly
adjusted
loss of 86 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -76 cents.  The mean expectation of nine analysts for the
quarter was for a loss of $1.01 per share. Wall Street expected
results to range from $-1.26 to -40 cents per share.
    * Revenue fell 66% to $16.79 million from a year ago;
analysts
expected $12.15 million. 
    * Vir Biotechnology Inc's reported EPS for the quarter was a
loss
of 86 cents​.
    * The company reported a quarterly loss of $115.97 million.
    * Vir Biotechnology Inc shares had risen by 0.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Vir Biotechnology
Inc is $21.00 
This summary was machine generated from LSEG data February 23 at
03:04 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.01          -0.86          Beat
 Sep. 30 2023      -1.21          -1.22          Missed
 Jun. 30 2023      -1.20          -1.45          Missed
 Mar. 31 2023      -0.87          -1.06          Missed